港股异动 | 同方康泰大涨逾64% 康乐制药已恢复生产及制作原料药磷酸氯喹
格隆汇2月4日丨同方康泰(1312.HK)现报0.217港元,大涨64.39%,暂成交2434万港元,最新总市值12.1亿港元。同方康泰昨晚宣布,集团接获中国工业和信息化部消费品司、重庆市经济和信息化委员会与重庆市长寿区经济和信息化委员会的通知,磷酸氯喹被测试及证实就对抗新型冠状病毒感染的肺炎 ("2019新型冠状病毒")有一定的疗效。公司间接非全资附属公司重庆康乐制药早前已获国家药品监督管理局认可为生产原料药磷酸氯喹的单位,鉴于对抗新冠病毒有一定疗效,被工业和信息化部消费品司要求尽快恢复原料药磷酸氯喹的生产及制作。于公告日期,康乐制药已恢复生产及制作原料药磷酸氯喹。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.